庐阳区439例低出生体重儿资料分析

目的:分析低出生体重儿的有关数据,了解低出生体重儿的现状。方法:对2001～2007年合肥市庐阳区439例低出生体重儿的资料进行回顾性分析。结果:2001～2007年该区低出生体重儿的发生率为2.72%,每年发生率无明显变化。结论:①应指导孕妇合理饮食,避免接触有毒物质,加强孕期保健管理,减少低出生体重儿的出生;②加强低出生体重儿保健指导,促进低出生体重儿的生长发育,提高儿童的生活质量。     

鼻内镜下低温等离子射频消融治疗中轻度慢性肥厚性鼻炎237例临床观察

目的 观察鼻内窥镜下低温等离子消融治疗中轻度慢性肥厚性鼻炎的效果,探索治疗慢性肥厚性鼻炎的新方法. 方法在鼻内镜直视下40-70度低温射频等离子对237例中轻度慢性肥厚性鼻炎患者消融治疗. 结果一次治疗6月后237例患者中痊愈221例(93.2%),有效13例5.5 %),无效3例(1.3%).结论 鼻内镜下低温等离子射频消融治疗中轻度慢性肥厚性鼻炎视野清楚、操作简易,安全、出血少,疗效好,值得推广.     

骨折患者的中医整体护理

骨折是骨的完整性或连续性中断的一类疾病,卧床时间长,担心预后,患者不但承受着肉体上的痛苦,还承受着精神压力,若护理不当,不但会给患者造成躯体的疼痛,影响骨折愈合,甚至发生一系列的并发症.现将骨折患者的中医整体护理介绍如下.     

错配修复基因（蛋白hMSH2）在子宫内膜癌中的表达及意义

资料与方法 2003年4月～2007年8月20例来本院就诊的正常子宫内膜患者,手术治疗子宫肌瘤的正常内膜,其中增生期内膜10例,分泌期内膜10例。     

细冰合剂滴鼻对大鼠脑缺血再灌注损伤保护作用的实验研究

目的观察细冰合剂滴鼻对大鼠脑缺血再灌注脑梗死体积及脑含水量的作用。方法SD雄性大鼠随机分为假手术组、模型组、细辛组、冰片组、细冰合剂及尼莫地平阳性对照组。术前各治疗组连续滴鼻3d,对照组给予腹腔注射尼莫地平,均于末次给药30min后行手术,采用线栓法制备大鼠大脑中动脉缺血再灌注损伤模型,缺血1h再灌注24h后进行神经功能学评分 测脑组织梗死体积、脑指数及脑含水量。结果与假手术组比较,模型组神经功能学评分、脑组织梗死体积、脑指数及脑含水量差异有统计学意义（P〈0.01） 与模型组比较,细冰合剂组脑梗死范围有一定缩小（P〈0.05）,脑指数、脑含水量及神经功能学评分明显降低（P〈0.05）。结论细冰合剂能减轻脑缺血再灌注大鼠的脑水肿程度,减少脑组织的梗死体积,对脑缺血再灌注损伤有一定的保护作用。     

Severe psychiatric problems in right hepatic lobe donors for living donor liver transplantation

BACKGROUND: The morbidity and mortality from donation of a right hepatic lobe for living donor liver transplantation (LDLT) is an important issue for this procedure. We report the prevalence of severe psychiatric postoperative complications from the Adult-to-Adult Living Donor Liver Transplantation Cohort study (A2ALL), which was established to define the risks and benefits of LDLT for donors and recipients. METHODS: Severe psychiatric complications were evaluated in all donors from the A2ALL study who were evaluated between 1998 and February 2003. RESULTS: Of the 392 donors, 16 (4.1%) had one or multiple psychiatric complications, including three severe psychiatric complications (suicide, accidental drug overdose, and suicide attempt). CONCLUSIONS: Despite extensive preoperative screening, some donors experience severe psychiatric complications, including suicide, after liver donation. Psychiatric assessment and monitoring of liver donors may help to understand and prevent such tragic events.     

Population pharmacokinetic analysisof lamivudine,stavudine and zidovudine in controlled HIV-infected patients on HAART

Objective This work aimed at building a population pharmacokinetic (PK) model for lamivudine (LMV), stavudine (STV) and zidovudine (ZDV), estimating their inter and intraindividual PK variability and investigating the influence of different covariates. Methods Population PK of LMV, STV and ZDV was separately evaluated from plasma concentrations obtained in 54, 39 and 27 HIV1-infected patients, respectively, enrolled in the COPHAR1-ANRS102 trial. The primary objective of this trial was to study the pharmacokinetics of indinavir (IDV) and nelfinavir (NFV) in treated patients with a sustained virological response. Concentrations of nucleoside analogs (NA) were measured in plasma as a secondary objective. A one-compartment model with first-order elimination was used, with zero-order absorption for LMV and first-order absorption for STV and ZDV. Results Mean parameters [interpatient variability in coefficient of variation (CV%)] of LMV, STV and ZDV were: oral volume of distribution (V/F) 145 l (52%), 24 l (81%) and 248 l (80%), oral clearance (Cl/F) 32 l/h, 16 l/h (74%) and 124 l/h (51%), respectively. For LMV, absorption duration (T _a ) was 1.46 h (64%). For STV and ZDV, k _a was 0.46 h⁻¹ and 2.9 h⁻¹, respectively. We found a systematic effect of combination with NFV vs. IDV. We found that intrapatient variability was greater than interpatient variability (except for STV) and greater than 55% for the three drugs. Conclusion This trial enabled the estimation of the population PK parameters of three NA in patients with a sustained virological response, and the median curves could be used as references for concentration-controlled strategies. We observed, as for the protease inhibitors, a great variability of PK parameters.     

我国部分地区慢性HBV感染者HDV感染情况调查

目的 了解目前我国部分地区慢性HBV感染者丁型肝炎病毒(HDV)感染流行情况。方法 2021年3月—2022年6月从全国10个省市自治区收集3 131例慢性HBV感染者血清,用抗-HDV IgG酶联免疫试剂检测全部血清标本。对抗-HDV IgG阳性标本用巢式逆转录聚合酶链式反应(nRT-PCR)法检测HDV RNA。对HDV RNA阳性标本的nRT-PCR扩增产物测序后进行序列分析,确定HDV基因型。分析抗-HDV IgG阳性患者的临床特征。计量资料两组间比较采用Mann-Whitney U秩和检验。计数资料两组间比较采用χ²检验或Fisher精确检验。结果 3 131例慢性HBV感染者的抗-HDV IgG阳性率为0.70%(22/3 131),内蒙古自治区、新疆维吾尔自治区、北京市和湖南省慢性HBV感染者的抗-HDV IgG阳性率分别为1.81%(16/886)、0.88%(2/226)、0.28%(2/708)和1.00%(2/200),其中内蒙古自治区慢性HBV感染者抗-HDV IgG阳性率显著高于北京市(P=0.004),其余地区间比较差异均无统计学意义(...